Medial EarlySign For Profit

EarlySign, also known as Medial EarlySign, is a company that specializes in developing a clinical AI platform for early detection of high-burden diseases for those who are likely at risk of complications from serious disease. They work with physicians, scientists, and engineers to provide predictive insights for recommending assessment for early detection of potential complications from different diseases and chronic conditions. Their solutions utilize predictive models that can detect individuals more likely to have a serious condition based on ML-based analysis of the information from existing clinical data. EarlySign partners with healthcare organizations to deliver patient-level, actionable insights directly into existing clinical workflows. They prioritize and invest resources and effort to independently validate their research in multiple environments leading to recognition and publication in multiple peer-reviewed journals. Contact info: N/A.

Total Funding: 50000000
Headquarters: Hod Hasharon, HaMerkaz, Israel
Funding Status: Early Stage Venture
Employee Number: 11-50
Estimated Revenue: $1M to $10M
Investment Stage: N/A
Last Funding Type: Series B
Number Of Exists: N/A
Technology: Biomarker panels
Investor Type: N/A
Last Funding Date: 2018-03-06
Investors Number: 5
Founded Date: 2009-01-01
Industry: Clinical Data Management